A prospective clinical study on the effectiveness of Phellinus igniarius decoction in treating immune dysfunction in colorectal cancer patients following chemfotherapy Authors: Huihui Zhang, Weihang Li, Die Hu, Wentao Hu, Ting Wang, Panling Xu, Ping Li Published: 2026 ABSTRACT AbstractBackground and aimChemotherapy for colorectal cancer (CRC) frequently induces immune dysfunction, which can negatively affect patient prognosis. Phellinus igniarius, a traditional Chinese medicinal fungus, exhibits immunomodulatory potential, yet clinical evidence supporting its use in postchemotherapy immune recovery remains scarce. This study aimed to evaluate the efficacy and safety of Phellinus igniarius Decoction (PEG) in treating postchemotherapy immune dysfunction in patients with CRC and identify potential beneficiaries.Experimental procedureThis prospective, randomized, controlled trial enrolled patients with CRC who completed chemotherapy between January 2021 and June 2024. Participants were randomized (1:4:1) to receive placebo (N = 33), PEG (N = 132), or thymalfasin (N = 33). Thymalfasin (1.6 mg subcutaneously twice weekly), PEG (15 g/day orally), or placebo was administered for 8 weeks. Primary outcomes included changes in peripheral blood immune cell subsets (CD4+/CD8+ ratio and percentage of NK cells) and cytokines (Th1/Th2 balance). Secondary outcomes included quality of life (QOL) scores (EORTC QLQ-C30) and adverse events. Finally, the dominant Traditional Chinese Medicine (TCM) syndrome type in the PEG group was identified.Results and conclusionThe PEG group demonstrated significant increases in the proportions of CD4+ T cells (p < 0.001), the percentage of NK cells (p < 0.05), and the levels of Th1 cytokines (IL-2 and IFN-γ), and a reduction in the levels of Th2/inflammatory factors (IL-4, IL-10 and TNF-α) (p < 0.05). It also improved quality of life scores (p < 0.05), with adverse event rates comparable to those of the controls. Subgroup analysis revealed that patients with spleen-kidney deficiency syndrome composed the optimal responder subgroup. PEG effectively restored immune function, improved quality of life, and was favorable for in postchemotherapy patients with CRC, with those exhibiting spleen-kidney deficiency syndrome representing the primary beneficiary population.Keywords: Phellinus igniarius decoction, Colorectal cancer, Chemotherapy-induced immune dysfunction, Th1/Th2 balance, Randomized controlled trial Introduction Colorectal cancer (CRC) is among the most prevalent and lethal malignant neoplasms worldwide1, 2, 3, 4. Although some progress has been made in the development of chemotherapy regimens for the treatment of colorectal cancer, chemotherapy-induced immune damage is still an important factor affecting the therapeutic efficacy and prognosis of patients5, 6, 7. Immunosuppression not only aggravates the immune escape of tumors, but also makes patients prone to infection, further exacerbating disease progression8, 9, 10, 11, 12. Therefore, finding effective immunomodulatory therapy has become a key issue in clinical treatment. Phellinus igniarius (Sanghuang), also known as mulberry, is a traditional Chinese herb with significant immunomodulating effects. Recent basic research has shown that Phellinus igniarius has good effects in enhancing immune function, especially in cancer immunotherapy.13 Yoo et al. reported that Phellinus igniarius enhanced the immune response in cyclophosphamide-induced immunosuppressed mice.14 Furthermore, Phellinus igniarius effectively stimulate the anti-inflammatory activity of RAW264.7 cells.15 There is currently insufficient clinical evidence to support its use for immune recovery in patients with CRC after chemotherapy. This study aimed to bridge this gap by evaluating the effects of PEG on immune recovery and QOL in a prospective trial. Methods Study design and participants We conducted a randomized study in 3 research centers. The eligibility criteria encompassed patients aged 18 years or older who had undergone surgical intervention and completed standard adjuvant chemotherapy and who subsequently developed immune impairment following a pathological diagnosis of colorectal cancer. Immune impairment is defined as a CD4+/CD8+ ratio less than 1.4 in peripheral blood.16 an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2 and normal organ function. Additionally, participants must have provided informed consent and be enrolled in the study at the principal hospital. Exclusion criteria include individuals with severe immune system disorders (e.g., systemic lupus erythematosus, rheumatological conditions), primary immunodeficiencies, use of alternative immune-modulating medications in the past 3 months, hypersensitivity to traditional Chinese medicine components, or those who are pregnant or breastfeeding. The trial was conducted in accordance with the Good Clinical Practice guidelines established by the International Conference on Harmonization and in accordance with the protocol. The protocol was approved by the institutional review board or independent ethics committee at each site (NO. PJ-2020-03-50). All the patients provided written informed consent in accordance with the principles of the Declaration of Helsinki. An independent data monitoring committee monitored safety and efficacy data. Randomization and syndrome differentiation of TCM Patients were randomly assigned at a 1:4:1 ratio to receive thymalfasin, PEG or placebo for 8 weeks. This allocation design prioritized a larger sample size in the PEG group (n = 132) to support exploratory analyses of TCM syndrome patterns, which were identified post hoc on the basis of clinical presentations during data collection. The enlarged PEG group was justified to ensure adequate statistical power for subgroup analyses, as the distribution of the syndrome could not be predetermined. Randomization was performed with the use of a computer-generated random-number table. Allocation concealment was ensured using sealed envelopes. Blinding was maintained for the placebo and PEG groups, although the distinct taste of PEG posed a potential limitation. According to the six sets of diagnostic information collected, syndrome differentiation was performed in patients who received PEG. The syndrome standards for internal dampness-heat, deficiency of the spleen and kidney, deficiency of qi and blood, deficiency of the spleen and qi stagnation, internal obstruction of blood stasis and toxins, deficiency of yin in the liver and kidney, and other patterns were defined according to the syndrome differentiation types of colorectal cancer in the 24 specialties and 105 disease categories of traditional Chinese medicine treatment plans.17 Procedures Patients underwent routine blood testing within 1 month of adjuvant chemotherapy completion to confirm immunosuppression. Following randomization, patients in the thymalfasin group received 1.6 mg subcutaneous injections twice weekly, with a 3–4 day interval between doses, for 8 consecutive weeks. For patients in the PEG group, 15 g of dried Sanghuang (Phellinus igniarius) slices were decocted in 200 mL of water for 30 min, the supernatant was collected, and the residue was decocted a second time in 200 mL of water for 30 min. The two supernatants were combined and administered orally twice-daily for 8 weeks. Patients in the placebo group received an identical decoction regimen using a matched placebo lacking active ingredients. After 8 weeks of intervention, all patients underwent blood sampling for immune function assessment and quantification of cytokine levels. Outcomes The primary endpoint of this study was immune function, which was assessed via the following: 1) T-cell subsets (CD4+ and CD8+); 2) the proportion of natural killer (NK) cells; and cytokines (IL-2, IFN-γ, IL-4, IL-10 and TNF-α). All immune function tests were performed before and after 8 weeks of treatment. The secondary endpoints included quality of life scores (EORTC QLQ-C30) and adverse events. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) is a quality of life assessment tool developed by the European Organization for Research and Treatment of Cancer (EORTC), which is widely used in various cancer studies to evaluate the quality of life of patients with cancer during and after treatment.18 Adverse events included nausea, vomiting, diarrhea and fatigue.19 Statistical analysis The data were analyzed using SPSS v26. Measurement data are expressed as the mean ± standard deviation (SD), and independent sample t tests, Mann-Whitney U tests or ANOVA were used for comparisons between groups. Count data are expressed as frequency and percentage, frequencies and percentages, and the chi-square test was used for comparisons between groups. All the statistical tests were two-sided, and p < 0.05 was considered to indicate statistical significance. Results From January 2021 to June 2024, 240 patients at three centers were assessed for eligibility and 198 patients were included in this study. The patients were randomly divided into groups in a 1:4:1 ratio by digital random method. The flow chart is shown in Fig. 1. Flow chart for this study. Baseline characteristics The baseline parameters were compared among the three groups of patients. No significant differences in age, sex, BMI, TNM stage, education level or occupation were detected among the groups (Table 1). Table 1Baseline characteristics of patients in this study.Table 1VariableTotal n = 198Placebo group n = 33PEG group n = 132Thymalfasin group n = 33pAge, years, mean ± SD65.52 ± 8.9562.75 ± 11.2963.48 ± 10.470.465Sex, men, n (%)17 (51.5)55 (41.7)19 (57.6)0.204Occupation, n (%)Intellectual7 (21.2)42 (31.8)9 (27.3)0.322Manual13 (39.4)29 (22)10 (30.3)Retired13 (39.4)61 (46.2)14 (42.4)Education level, n (%)Undergraduate or above11 (33.3)48 (36.4)8 (24.2)0.736Secondary school10 (30.3)43 (32.6)12 (36.4)Primary school12 (36.4)41 (31.1)13 (39.4)BMI, kg/m2, mean ± SD21.34 ± 2.321.06 ± 1.9821.60 ± 2.090.244TNM, n (%)II18 (46.5)59 (44.7)15 (45.5)0.593III15 (53.5)73 (55.3)18 (54.5) Baseline characteristics of patients in this study. Immune function The changes in immune-related indicators and cytokines, including the CD4+/CD8+ T-cell ratio, percentage of NK cells, white blood cell count (WBC), and cytokine levels. at weeks 0 and 8 across the different treatment groups are shown in Fig. 2. At week 8, compared with the placebo group, both the PEG and thymalfasin groups had significantly higher CD4+/CD8+ ratios (p < 0.001). The percentage of NK cells in the PEG group increased significantly from baseline (p < 0.05) and was significantly higher than that in the placebo group at week 8 (p < 0.05). Regarding WBC count, both the PEG and thymalfasin groups exhibited a significant increase in white blood cell count at 8 weeks (p < 0.05), whereas compared with its baseline value, no significant changes were observed in the placebo group. Th1 cytokines (IL-2 and IFN-γ) were significantly elevated in the PEG group, whereas Th2 (IL-4) and immunosuppressive factors (IL-10 and TNF-α) were decreased, suggesting that it enhances anti-tumor immunity by re-establishing the Th1/Th2 balance. Changes in immune-related indicators at weeks 0 and 8 across different treatment groups. (A) CD4+CD8+ T-cell percentages, (B) NK cell percentage, (C) white blood cell (WBC) count, (D) IL-2 concentration (pg/mL), (E) IFN-γ concentration (pg/mL), (F) IL-4 concentration (pg/mL), (G) IL-10 concentration (pg/mL), and (H) TNF-α concentration (pg/mL) (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). EORTC QLQ-C30 score The EORTC QLQ-C30 is one of the most widely used scales in cancer research, primarily designed to assess various domains of quality of life in cancer patients. This study utilized five functional scales to evaluate physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning, as well as nine symptom scales to assess different symptoms experienced by patients with cancer. Each item was scored using the 4-point Likert scale, where 1 indicates “not at all” and 4 indicates “very poor”. In accordance with the scale's guidelines, functional scale scores were linearly converted to a 0–100 scale, with higher scores indicating better functional status. Higher scores on symptom scales or individual items indicate more severe symptoms. Compared with the placebo group, the PEG group showed significant improvements in quality of life at week 8, specifically in terms of global health status; physical function; role function; emotional function; and symptoms, including fatigue, nausea and vomiting, pain, insomnia, appetite loss, and constipation (p < 0.05) (Fig. 3A). Specifically, the depicts changes in global health status across the three groups at baseline (week 0) and post-treatment are shown in Fig. 3B. Both the PEG and thymalfasin groups showed significant improvements in global health score from baseline (p < 0.05), and the scores in both intervention groups were significantly greater than those in the placebo group at week 8 (p < 0.05). Changes in quality of life (QOL) scores. (A) Changes in multiple quality of life scores at week 8 across the three groups. (B) Changes in global health status across the groups. The data points represent the mean, and the error bars indicate the standard deviation (∗p < 0.05). Treatment-related adverse events During the treatment process, we observed and recorded the occurrence of treatment-related adverse events in each group of patients, and the results are shown in Table 2. Adverse events were statistically classified into grades 1–2 and grades 3 and above according to severity. Between-group comparisons revealed that the incidence rates of nausea and vomiting, appetite loss, fatigue, insomnia, and constipation in the PEG group were significantly lower than those in both the placebo and thymalfasin groups (p < 0.05). No significant differences were observed in the incidence of other adverse events (e.g., anemia, rash) across the three groups (p ≥ 0.05). Overall, most adverse events were Grade 1–2. The results revealed that the Sanghuang group had better tolerance and safety in terms of improving chemotherapy-related adverse events. Table 2Incidence of treatment-related adverse events.Table 2Treatment related adverse events n (%)Placebo groupn = 33PEG groupn = 132Thymalfasin groupn = 33pGrade 1-2Grade ≥3Grade 1-2Grade ≥3Grade 1-2Grade ≥3Nausea and vomiting8 (24.2)1 (3.0)5 (3.7)06 (18.1)0<0.001Anemic2 (6.1)010 (7.6)02 (6.1)00.926Leucopenia4 (12.1)016 (12.1)2 (1.5)5 (15.1)1 (3.0)0.747Neutropenia4 (12.1)016 (12.1)2 (1.5)5 (15.1)1 (3.0)0.747Hand-to-foot syndrome2 (6.1)05 (3.7)02 (6.1)00.770Alopecia4 (12.1)010 (7.6)03 (9.1)00.702AST/ALT raise4 (12.1)014 (10.6)05 (15.1)00.763Rashes3 (9.1)012 (9.1)02 (6.1)00.851Weight loss4 (12.1)016 (12.1)05 (15.1)00.892Loss of appetite7 (21.2)08 (6.1)06 (18.1)00.012Fatigue6 (18.1)04 (0.03)05 (15.1)00.003Insomnia8 (24.2)05 (3.0)07 (21.2)0<0.001Constipation6 (18.1)010 (7.6)08 (24.2)00.016Asthma3 (9.1)07 (5.3)02 (6.1)00.717 Incidence of treatment-related adverse events. Comparison and advantageous screening of different evidence types In this study, 132 patients with intestinal cancer and postchemotherapy immune impairment in the Sanghuang group were analyzed for TCM syndrome types, which were classified as dampness-heat intrinsic (n = 32), spleen-kidney deficiency (n = 23), qi-blood deficiency (n = 21), spleen deficiency and qi-stagnation (n = 18), internal blockage of stasis toxin (n = 17), liver-kidney yin deficiency (n = 11) and other syndrome types (n = 10). Further evaluation of immune recovery of patients across different syndrome types revealed that patients with spleen-kidney deficiency syndrome type (n = 23) showed the best immune recovery. As shown in Table 3, compared with the other syndrome types, the spleen-kidney deficiency group demonstrated significantly better immune function reconstitution (NK cell percentage) and cytokine regulation (IFN-γ and TNF-α). These findings suggest that this type of syndrome is dominant in the treatment of Sanghuang. However, caution is warranted when interpreting subgroup results because of the limited sample sizes. Post hoc power analysis indicated insufficient power for the liver–kidney Yin deficiency subgroup (n = 11) to detect clinically meaningful differences. Thus, the results from smaller subgroups (n < 15) should be considered exploratory. Table 3Immune indicators in colorectal cancer chemotherapy patients with different traditional chinese medicine syndromes.Table 3VariableInternal dampness-heatDeficiency of the spleen and kidneyDeficiency of qi and bloodDeficiency of the spleen and qi stagnationInternal obstruction of blood stasis and toxinDeficiency of yin in the liver and kidneyOthers(n = 32)(n = 23)(n = 21)(n = 18)(n = 17)(n = 11)(n = 10)CD4+/CD8+ ratio1.38 ± 0.331.52 ± 0.301.40 ± 0.341.35 ± 0.321.43 ± 0.351.39 ± 0.311.45 ± 0.29NK cell percentage21.5 ± 10.125.3 ± 9.5∗20.2 ± 10.319.8 ± 10.022.0 ± 10.418.5 ± 9.620.8 ± 10.0WBC (×109/L)6.15 ± 2.606.35 ± 2.555.80 ± 2.505.95 ± 2.586.20 ± 2.705.70 ± 2.456.00 ± 2.60IL-2 (pg/mL)18.2 ± 4.020.5 ± 3.818.0 ± 4.117.5 ± 3.719.0 ± 4.217.8 ± 4.018.5 ± 3.9IFN-γ (pg/mL)37.5 ± 7.642.0 ± 7.2∗38.5 ± 7.536.8 ± 7.339.2 ± 7.837.0 ± 7.138.5 ± 7.4IL-4 (pg/mL)6.8 ± 1.75.2 ± 1.66.5 ± 1.86.0 ± 1.76.3 ± 1.76.1 ± 1.86.2 ± 1.7IL-10 (pg/mL)10.5 ± 3.08.0 ± 2.89.8 ± 3.19.5 ± 3.010.0 ± 3.29.2 ± 3.19.6 ± 3.0TNF-α (pg/mL)19.5 ± 5.115.5 ± 4.8∗18.0 ± 5.017.8 ± 5.218.5 ± 5.317.2 ± 4.917.9 ± 5.0∗Compared with the other groups p < 0.05 (statistical comparisons not performed for subgroups with n < 15 because of inadequate power). Immune indicators in colorectal cancer chemotherapy patients with different traditional chinese medicine syndromes. ∗Compared with the other groups p < 0.05 (statistical comparisons not performed for subgroups with n < 15 because of inadequate power). Discussion This study confirms for the first time through a prospective randomized controlled trial that PEG can significantly improve the immune function impairment after chemotherapy in patients with intestinal cancer. The results showed that patients in the PEG group were significantly better than the placebo group in terms of CD4+/CD8+ T-cell ratio, NK cell proportions and Th1-type cytokine (IL-2 and IFN-γ) levels (p < 0.05), and Th2/inflammatory factors (IL-4, IL-10 and TNF-α) were significantly down-regulated, suggesting that it enhances the anti-tumor immunity by re-establishing the balance of Th1/Th2. In addition, the quality of life scores of the patients in the PEG group were significantly improved, and the incidence of symptoms such as nausea and vomiting, insomnia, and so on was significantly lower in the PEG group than in the placebo group (p < 0.05), suggesting that it not only improves the immune function but also alleviates the symptoms related to chemotherapy. Notably, there was no significant difference in the immune recovery effect between the PEG group and the thymalfasin group, but the incidence of adverse reactions was lower in the PEG group, suggesting its potential advantage in terms of safety. Although our research focused on short-term outcomes, the prognostic significance of immune reconstitution has been preliminarily confirmed: pretreatment Th1 deficiency and Th2 skewing predict poor chemotherapy response, whereas responders exhibit sustained Th1 elevation post-treatment20, 21, 22. Similarly, an elevated CD4+/CD8+ ratio independently predicts prolonged DFS/OS in patients with CRC.23 Our findings suggest that PEG restores Th1/Th2 balance and increases the CD4+/CD8+ T-cell ratio thus providing a mechanistic rationale for the potential long-term benefits of this treatment. Moreover, PEG significantly alleviated chemotherapy-induced symptoms (nausea, fatigue, insomnia; Table 2) and improved QoL (EORTC QLQ-C30; Fig. 3). This enhanced treatment tolerance may improve adherence to subsequent therapies (e.g., maintenance chemotherapy), indirectly supporting sustained disease control. While direct survival data require future validation, the convergence of immune restoration, symptom relief, and QoL improvement underscores the potential of PEG to confer durable clinical benefits. Longer-term follow-up studies are necessary to assess whether these initial benefits can translate into sustained immune reconstitution and survival advantages. The immunomodulatory effect of PEG may be related to its multicomponent synergistic effect. Previous studies have confirmed that polysaccharides and flavonoids in PEG may improve immune function by activating dendritic cells, promoting T-cell differentiation and enhancing NK-cell activity.14 In our previously published basic research, we performed comprehensive chemical analysis of PEG extracts and identified its main components, including phenols and glycosides. The top 10 components were sesamol, turanose, (4e,8e)-n-d-2′-hydroxypalmitoyl-1-o-β-d-glucopyranosyl-9-methyl-4,8-spingodienine, luciferin, trehalose, osmundacetone, adenosine, citric acid, ethyl caffeic acid, and epicatechin gallate. Additionally, we identified blood components in Phellinus igniarius extract, including mannitol, bombykol, guanosine, neoeriocitrin, 2-heptadecanone, beta-escin, erectquione b, and isolongifolen-9-one.24 The up-regulation of Th1 cytokines and down-regulation of Th2/inflammatory factors observed in this study suggest that PEG may regulate immune homeostasis by inhibiting the STAT6 signaling pathway, a key pathway for Th2 differentiation, or activating the TLR4/NF-κB pathway, which is associated with Th1 differentiation. This potential mechanism remains hypothetical and requires molecular validation (Fig. 4). In addition, the triterpenoid components in PEG have been shown to exert anti-inflammatory effects, which may attenuate chemotherapy-induced immunosuppression by inhibiting the release of pro-inflammatory factors such as TNF-α 14,25, 26, 27, 28, 29, 30, and Sanghuang mycelium has been reported to significantly inhibit the expression of pro-inflammatory factors TNF-α and IL-6.31 It is necessary to emphasize that the PEG decoction used in this clinical study had not undergone chemical composition analysis. The component identification results of the Phellinus igniarius alcohol extract in another study by our team can only serve as a potential reference, and cannot be directly attributed to the active ingredient responsible for the therapeutic effect of the PEG decoction. The exact active components and mechanism of action of the PEG decoction remain unclear and require further research. Possible mechanism of PEG in the treatment of immune dysfunction after chemotherapy for colorectal cancer. Analysis of Chinese medicine evidence revealed that patients with spleen and kidney deficiency had the most significant immune response to PEG treatment. The NK cell percent, and IFN-γ were significantly higher in this group than in the other evidence types (p < 0.05), while the TNF-α concentration was significantly lower. This finding is consistent with the theory of Chinese medicine that “the spleen is the foundation of the latter day and the kidney is the foundation of the innate day”: patients with deficiency of spleen and kidney are more severely immunosuppressed due to the loss of essence of the spleen and kidney,32 PEG can regulate the immune microenvironment of patients by tonifying the spleen and kidney, benefiting qi and correcting the immune system. The results of this study provide evidence for the use of “evidence-based treatment” in tumor immunotherapy. There are several limitations in this study. First, the sample size is small (n = 132 in the PEG group; n = 11∼32 in each syndrome subgroup), especially the statistical efficacy of the liver-kidney yin deficiency group (n = 11), which is insufficient, and some differences may be missed. Future studies should prioritize larger cohorts for rare syndromes. Second, because of the short follow-up time (8 weeks), the long-term immune recovery effect and survival prognosis could not be evaluated. Although our findings demonstrate significant short-term immune restoration and quality-of-life improvements, future studies with extended follow-up periods (e.g., 6–12 months) are warranted to assess whether these benefits translate to sustained immune reconstitution, reduced infection rates, and prolonged PFS or OS. Such investigations would further validate the clinical relevance of the PEG in long-term cancer survivorship care. Third, the active components (such as polysaccharides and flavonoids) of Sanghuang were not quantitatively analyzed, which may affect the accuracy of the mechanism interpretation. Furthermore, although we implemented a placebo control and assessor blinding, the unique taste of PEG might have affected the blinding status of the subjects to some extent. This could reduce the reliability of patient-reported secondary endpoints (e.g., quality of life scores and symptom improvement) compared with the immunological primary endpoints, which are primarily derived from objective laboratory tests. Future studies may use taste-masking technologies or encapsulated extracts to improve the fidelity of blinding. Thus, the proposed molecular mechanism remains purely hypothetical as it lacks direct empirical validation. Although our clinical data are consistent with these pathways, we have not conducted transcriptomic or proteomic analyses to confirm target binding status. Future research should integrate multiomics methods to verify the impact of PEG on these pathways and identify new biomarkers. Finally, although our trial coincided with the COVID-19 pandemic, our randomized design and the consistency of baselines among the groups reduced major deviations; however, we did not systematically track specific variables related to the pandemic (such as infection history, vaccination status, or lifestyle changes due to lockdowns). Future studies should incorporate such monitoring to clarify the interference of these factors on immune-regulating intervention measures. Conclusion PEG can effectively improve chemotherapy-induced immunosuppression in patients with intestinal cancer, significantly increase the CD4+/CD8+ ratio, NK cell proportion and Th1-type cytokines; inhibit Th2/inflammatory factors; and alleviate nausea, vomiting, insomnia and other symptoms. Chinese medicine evidence analysis revealed that patients with spleen and kidney deficiency had the best immune recovery. In the future, we need to expand the sample size to verify long-term efficacy and to explore the active ingredients and molecular mechanisms to guide precise treatment. Credit author statement Huihui Zhang: study design, data collation, first draft writing; Weihang Li: experimental execution, data collection; Die Hu and Wentao Hu: case enrolment, efficacy assessment; Ting Wang: project management, dissertation revision; Panling Xu: statistical analysis, charting and graphing; Ping Li: research guidance, final draft validation, Funding acquisition. Funding This work was supported by Key Research and Development Program of Anhui Province in 2021 [grant numbers No. 202104a07020021]; 2022 Annual University Scientific Research Project of Anhui Province, China [grant numbers No. 2022AH051162] and 2023 Anhui Provincial University Collaborative Innovation Project [grant numbers No. GXXT-2023-074]. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgements Special thanks to Hefei Cubic Pharmaceutical Co., Ltd. and Jinzhai Shangzhen Biotechnology Co., Ltd. for drug sponsorship and technical support. Contributor Information Ting Wang, Email: wangting921204@ahmu.edu.cn. Panling Xu, Email: yfy1922775@fy.ahmu.edu.cn. Ping Li, Email: liping1964@ahmu.edu.cn. Data availability The data in this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data in this study are available from the corresponding author upon reasonable request.